Hood River Capital Management LLC Increases Stock Holdings in Augmedix, Inc. (NASDAQ:AUGX)

Hood River Capital Management LLC increased its holdings in shares of Augmedix, Inc. (NASDAQ:AUGX) by 79.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 490,238 shares of the company’s stock after buying an additional 216,339 shares during the quarter. Hood River Capital Management LLC owned about 1.00% of Augmedix worth $2,005,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Oppenheimer Asset Management Inc. purchased a new position in shares of Augmedix during the 1st quarter worth about $56,000. SG Americas Securities LLC acquired a new position in shares of Augmedix in the 1st quarter valued at $57,000. Norden Group LLC grew its stake in shares of Augmedix by 50.2% during the 1st quarter. Norden Group LLC now owns 19,152 shares of the company’s stock valued at $78,000 after buying an additional 6,401 shares during the period. Symmetry Peak Management LLC acquired a new stake in shares of Augmedix during the 4th quarter worth $88,000. Finally, PEAK6 Investments LLC purchased a new position in shares of Augmedix in the 1st quarter worth $112,000. 87.11% of the stock is owned by institutional investors and hedge funds.

Augmedix Stock Performance

Shares of AUGX remained flat at $2.27 during mid-day trading on Friday. 279,744 shares of the stock were exchanged, compared to its average volume of 1,897,684. The firm has a 50-day moving average of $1.09 and a two-hundred day moving average of $2.88. Augmedix, Inc. has a 12 month low of $0.73 and a 12 month high of $6.25. The company has a quick ratio of 2.04, a current ratio of 2.04 and a debt-to-equity ratio of 0.73.

Augmedix (NASDAQ:AUGX) last released its quarterly earnings results on Monday, May 13th. The company reported ($0.12) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.12). Augmedix had a negative net margin of 41.95% and a negative return on equity of 178.34%. The business had revenue of $13.47 million during the quarter, compared to analyst estimates of $13.25 million. Analysts expect that Augmedix, Inc. will post -0.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Evercore ISI downgraded Augmedix from an “outperform” rating to an “inline” rating and lowered their price target for the company from $5.00 to $1.50 in a research report on Tuesday, May 14th. Maxim Group lowered shares of Augmedix from a “buy” rating to a “hold” rating and set a $5.00 price target on the stock. in a report on Tuesday, May 14th. Lake Street Capital reiterated a “hold” rating on shares of Augmedix in a research note on Monday, July 22nd. B. Riley lowered shares of Augmedix from a “strong-buy” rating to a “hold” rating and dropped their price objective for the stock from $3.00 to $2.35 in a research report on Friday, July 19th. Finally, William Blair lowered shares of Augmedix from a “strong-buy” rating to a “hold” rating in a report on Friday, July 19th. Four equities research analysts have rated the stock with a hold rating, According to data from MarketBeat, Augmedix presently has a consensus rating of “Hold” and a consensus price target of $3.09.

Augmedix Profile

Augmedix, Inc provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits.